Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Endeavor Health, Evanston, IL 60201, USA.
Department of Obstetrics and Gynecology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA.
Nutrients. 2024 Sep 30;16(19):3318. doi: 10.3390/nu16193318.
Epidemiological and observational studies suggest that vitamin D has potential for the chemoprevention of ovarian cancer. The anticancer effect of vitamin D in the fallopian tube epithelium (FTE), which is now thought to harbor the precursor cells for high grade ovarian cancer, is not known. The purpose of this study was to investigate whether vitamin D can inhibit carcinogenesis in the mogp-TAg fallopian tube (FT) ovarian cancer mouse model and examine underlying mechanisms. To test this hypothesis, 3 groups of 40 5-week-old female mogp-TAg mice were divided equally into two cohorts of 20 mice, treated with either vehicle (vitamin D solvent) or the active 1,25(OH)2D3 analogue EB1089, delivered via mini-pump or IP injection or cholecalciferol delivered in the feed. The FTs were characterized histologically and pathologically after 3 and 7 weeks of treatment. The effect of vitamin D on cultured human FTE cells was also examined. After 3 weeks, vitamin D, delivered as either cholecalciferol or EB1089 significantly inhibited FT carcinogenesis. After 7 weeks, cholecalciferol significantly reduced p53 signatures, serous tubal epithelial carcinoma, FT cancer, and plasma CA125 while increasing apoptosis in the FTE. EB1089 had no significant effect on FT carcinogenesis at 7 weeks. Cholecalciferol significantly reduced proliferation and increased apoptosis in vitro in p53-altered FTE cells. In conclusion, vitamin D inhibited FT carcinogenesis by clearing cells with p53 alterations. These data suggest that vitamin D has merit for the chemoprevention of fallopian tube/ovarian cancer. The optimal chemopreventive effect may be dependent on the route of vitamin D administration.
流行病学和观察性研究表明,维生素 D 具有预防卵巢癌的潜力。维生素 D 在输卵管上皮(FTE)中的抗癌作用尚不清楚,而 FTE 现在被认为是高级别卵巢癌的前体细胞所在的部位。本研究旨在探讨维生素 D 是否可以抑制 mogp-TAg 输卵管(FT)卵巢癌小鼠模型中的癌变,并研究其潜在机制。为了验证这一假设,将 3 组 40 只 5 周龄的 mogp-TAg 雌性小鼠分为两组,每组 20 只,分别用载体(维生素 D 溶剂)或活性 1,25(OH)2D3 类似物 EB1089 治疗,通过迷你泵或 IP 注射或饲料中添加胆钙化醇进行治疗。在治疗 3 周和 7 周后,对 FT 进行组织学和病理学特征分析。还研究了维生素 D 对培养的人 FTE 细胞的影响。3 周后,以胆钙化醇或 EB1089 形式给予的维生素 D 显著抑制了 FT 癌变。7 周后,胆钙化醇显著降低了 p53 标志物、浆液性输卵管上皮癌、FT 癌和血浆 CA125,同时增加了 FTE 中的细胞凋亡。EB1089 在 7 周时对 FT 癌变没有显著影响。胆钙化醇显著降低了体外 p53 改变的 FTE 细胞的增殖并增加了其凋亡。总之,维生素 D 通过清除具有 p53 改变的细胞来抑制 FT 癌变。这些数据表明,维生素 D 对预防输卵管/卵巢癌具有一定的效果。最佳的化学预防效果可能取决于维生素 D 的给药途径。